You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

MOMETASONE FUROATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for mometasone furoate and what is the scope of patent protection?

Mometasone furoate is the generic ingredient in eight branded drugs marketed by Organon Llc, Organon, Anda Repository, Cosette, Fougera Pharms, Glenmark Pharms Inc, Taro, Intersect Ent Inc, Encube, Glenmark Pharms Ltd, Padagis Israel, Padagis Us, Torrent, Amneal, Amneal Pharms, Apotex, Aurobindo Pharma, Perrigo Pharma Intl, and Glenmark Specialty, and is included in thirty-one NDAs. There are twenty-seven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Mometasone furoate has forty-seven patent family members in twelve countries.

There are twenty-seven drug master file entries for mometasone furoate. Twenty-four suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for MOMETASONE FUROATE

See drug prices for MOMETASONE FUROATE

Drug Sales Revenue Trends for MOMETASONE FUROATE

See drug sales revenues for MOMETASONE FUROATE

Recent Clinical Trials for MOMETASONE FUROATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Phase 2
Centre hospitalier de l'Université de Montréal (CHUM)Phase 4
SandozPhase 1

See all MOMETASONE FUROATE clinical trials

Generic filers with tentative approvals for MOMETASONE FUROATE
Applicant Application No. Strength Dosage Form
⤷  Try a Trial⤷  Try a Trial0.05MG/SPRAYSPRAY, METERED;NASAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for MOMETASONE FUROATE
Medical Subject Heading (MeSH) Categories for MOMETASONE FUROATE
Paragraph IV (Patent) Challenges for MOMETASONE FUROATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NASONEX Nasal Spray mometasone furoate 50 mcg/ Spray 020762 1 2009-08-07
ELOCON Topical Solution (Lotion) mometasone furoate 0.1% 019796 1 2004-06-10

US Patents and Regulatory Information for MOMETASONE FUROATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo Pharma Intl NASONEX 24HR ALLERGY mometasone furoate SPRAY, METERED;NASAL 215712-001 Mar 17, 2022 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Organon ELOCON mometasone furoate OINTMENT;TOPICAL 019543-001 Apr 30, 1987 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Apotex MOMETASONE FUROATE mometasone furoate SPRAY, METERED;NASAL 091161-001 Mar 22, 2016 AB RX No Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Organon Llc ASMANEX HFA mometasone furoate AEROSOL, METERED;INHALATION 205641-002 Apr 25, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MOMETASONE FUROATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon Llc NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 ⤷  Try a Trial ⤷  Try a Trial
Organon Llc ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 ⤷  Try a Trial ⤷  Try a Trial
Organon Llc ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 ⤷  Try a Trial ⤷  Try a Trial
Organon Llc ASMANEX HFA mometasone furoate AEROSOL, METERED;INHALATION 205641-002 Apr 25, 2014 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for MOMETASONE FUROATE

Country Patent Number Title Estimated Expiration
European Patent Office 2429624 Combinaison d'un dispositif expansible et dispositif de mise en place (A combination of an expandable device and a delivery device.) ⤷  Try a Trial
Mexico 2007012324 DISPOSITIVO Y METODO PARA TRATAR CONDICIONES DEL SENO PARANASAL. (DEVICE AND METHODS FOR TREATING PARANASAL SINUS CONDITIONS.) ⤷  Try a Trial
Australia 2019201045 Systems, devices, and method for treating a sinus condition ⤷  Try a Trial
Japan 2008537695 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for MOMETASONE FUROATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3043773 132021000000191 Italy ⤷  Try a Trial PRODUCT NAME: MOMETASONE O UN SUO SALE E OLOPATADINA O UN SUO SALE(RYALTRIS); AUTHORISATION NUMBER(S) AND DATE(S): 048499014, 048499026, 048499038, 20210726;140638, 20210426
0548114 SPC/GB97/064 United Kingdom ⤷  Try a Trial PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
3043773 2022C/520 Belgium ⤷  Try a Trial PRODUCT NAME: MOMETASONE OF EEN ZOUT HIERVAN EN OLOPATADINE OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE595626 20220203
0112669 96C0002 Belgium ⤷  Try a Trial PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.